Ivan Wasserman, partner at Amin Talati Upadhye, has been awarded the 2017 Lexology Client Choice award for exemplary client service in the fields of Healthcare and Life Sciences in the District of Columbia. Read more MORE >see all news >
We support clients throughout the entire lifecycle of products aimed at improving the population's health and wellness: food and beverages, nutritional supplements, cosmetics, medical devices and pharmaceuticals.MORE
We provide counseling both to generic companies seeking to challenge patents and bring drugs to market, and to brand name pharmaceutical companies seeking to strategically patent and protect their brand name products in the long term.MORE
Drawing heavily on our IP, patent and trademark expertise, we provide our clients with business advice and strategies that enhance product value and head off future litigation.MORE
We are deeply experienced in FDA and FTC disputes, patent and trademark infringement cases, class actions, breach of contract and unfair competition claims. We are renowned in the area of Paragraph IV litigation, where companies challenge brand name patents so that medications can be marketed in generic forms.MORE
Law360, “A Look Back At The Top AIA-Related Decisions Of 2016” by Matthew Bultman. Bloomberg BNA’s Pharmaceutical Law & Industry Report: Joe Cwik Discusses Changing Landscape of Patent Infringement Litigation Due to New Inter Partes Review Process. To read the full article, please click HERE.
Ryan Kaiser was recently quoted in NOSH where he weighs in on the unique challenges of Amplify Snack Brand’s federal trademark infringement and unfair competition lawsuit battle with Snyder’s-Lance. To read the full article, please click HERE.
In response to a class action complaint filed against Dannon in late 2016, Ryan Kaiser answers questions such as “When will the FDA define ‘natural’?” and “Should ‘natural’ lawsuits be stayed while we wait?”. Please click HERE to read the full article from Food Navigator USA.